Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programs on software that hasn’t kept pace with science, leaving data siloed and relationships missing.

In this webinar, hosted by DDW, you’ll hear from Michael Strerath, Senior Scientific Director of Digital Transformation at Bayer, on how his team migrated off legacy systems to Benchling in early 2025 and rebuilt their registration foundation for modern antibody work. Michael will cover what drove the move, how Bayer now represents formats, domains, and relationships, and where automation and scientific sanity checks have changed how scientists work day-to-day.

Lily Helfrich from Benchling will set the scene on the shifting antibody landscape and the scientific fundamentals behind a modern data foundation for complex biologics, from mAbs to multispecifics and fusion proteins. We’ll also show Benchling Biologics: an antibody-aware data model, no-code format configuration, and automated registration that connects sequences to proteins to experimental context.

You’ll leave with a clearer picture of what modern antibody registration looks like in practice, and the lessons from Bayer you can apply in your own lab.

Watch on demand.